C hronic Lymphocytic Leukemia ( CLL ) is the most prevalent adult leukemia in the Western Hemisphere, currently affecting approximately 200,000 individuals in the United States. While the introduction of Bruton’s tyrosine kinase inhibitors (BTKis) like ibrutinib  has revolutionized treatment, these therapies present a significant long-term challenge: patients typically must remain on them indefinitely. This continuous treatment regimen not only carries the risk of long-term toxicity but also imposes a psychological burden, as the daily medication serves as a constant reminder of their illness. Recent research published in Clinical Cancer Research , a journal of the American Association for Cancer Research (AACR), presents a promising strategy to shift the treatment paradigm toward fixed-duration treatment . The study, led by senior author John C. Byrd, MD, investigated combining ibrutinib  with the investigational antibody ianalumab  (VAY736). The goal of this combination therapy was to achieve a deep enough response to allow patients to safely discontinue the daily ibrutinib  regimen. Preclinical studies had already suggested that ianalumab  would show superior activity when combined with BTKi drugs against CLL . Ianalumab functions by targeting the B-cell activating factor receptor (BAFR), which prevents cancerous B cells from surviving, while simultaneously marking these cells for destruction by the immune system's natural killer (NK) cells. Investigators conducted a phase I, open-label, multicenter trial involving 39 patients. These participants had not achieved complete remission on ibrutinib  alone or had developed resistance mutations. They received intravenous ianalumab  every two weeks alongside a standard dose of ibrutinib  for up to eight cycles. The results were highly encouraging: the combination therapy was well-tolerated, showing no dose-limiting toxicities. Importantly, the infection rates observed in this trial were actually lower than those historically reported with single-agent BTKi therapy, suggesting the addition of ianalumab  did not increase infection risk. Overall response was nearly 60%, and 43.6% of patients achieved undetectable measurable residual disease (uMRD) in their blood or bone marrow. Most significantly, 17 patients achieved a deep response—defined as uMRD in blood and/or bone—which allowed them to stop ibrutinib  and remain off therapy for periods ranging from 12 to 24 months. Dr. Byrd highlighted that for patients with blood cancers, being able to cease daily medication is "very symbolic" and removes the constant reminder of cancer, thus improving quality of life. These findings bolster the growing movement toward fixed-duration treatment  regimens in CLL  management. Such regimens are vital as they help patients avoid the cumulative toxicity associated with lifelong BTKi use, and they are also favored for their cost-effectiveness and potential to avoid the emergence of resistance. While existing treatment options already include other effective fixed-duration combinations, such as venetoclax plus obinutuzumab or venetoclax plus ibrutinib , the ianalumab  approach offers a new path for achieving remission deep enough to stop continuous BTKi reliance. Researchers noted that the current study is limited by its small sample size and lack of long-term follow-up, necessitating a larger trial to confirm if this strategy can become standard practice for reducing BTKi duration. Nevertheless, these initial results offer significant hope for patients seeking an end to lifelong CLL  therapy. A fixed-duration treatment  approach for cancer is like a scheduled course of antibiotics, rather than a vitamin you take forever. The goal is to deliver intense, comprehensive treatment over a set time period to eliminate the disease or drive it into deep remission, allowing the patient to enjoy a period free from medication and its associated side effects, a stark contrast to continuous, daily maintenance therapy. 🔖 Sources Combination therapy offers hope for ending lifelong chronic lymphocytic leukemia treatment A Combination Treatment May Help Cut Lifelong Ibrutinib for Chronic Lymphocytic Leukemia Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy Targeted Therapy Combinations Shine in Upfront CLL Treatment Keywords: Ianalumab and Ibrutinib Combination Ianalumab and Ibrutinib Combination

T he medical biotech sector is placing a massive bet on transforming the future of hair loss solutions, indicating a decisive move away from established, decades-old options such as Rogaine. This shift in focus and funding was emphatically illustrated by the recent announcement concerning Pelage Pharmaceuticals , which has secured a substantial new influx of capital positioning it prominently in the race for next-generation treatments. In a pivotal financial move reported in mid-October 2025, Pelage Pharma announced it successfully raised $120 million . This colossal sum was confirmed as a Series B financing  round. This significant level of financial backing underscores the burgeoning confidence among biotech investors that innovative, non-traditional solutions for hair loss are rapidly moving toward viability. This capital injection is not an isolated event; combined with funding raised by Veradermics, the total recent Biotech Investment  dedicated to innovative hair loss treatments reached a combined $270 million, highlighting a significant and unified research and market priority shift. For Pelage Pharmaceuticals , the $120 million Series B  is specifically allocated to accelerate its hair growth program . Critically, this financing is designated to support the advancement of the company’s novel approach toward regenerative medicine hair loss treatments . Regenerative medicine represents a deep, fundamental strategy that often seeks to stimulate the body’s intrinsic healing mechanisms or rebuild tissues, positioning it as potentially far more impactful than current topical or hormonal medications. The immediate application of the Series B funds will be to propel the company's research into its most advanced stages of clinical development. Specifically, this financing will support upcoming Phase 3 trials . Phase 3 trials are recognized as the critical, resource-intensive stage in the drug development pipeline, requiring conclusive patient outcomes before the company can pursue crucial regulatory approval. The financing news, released around October 14–15, 2025, detailed that, beyond supporting clinical trial preparation, the capital would also facilitate key board appointments necessary for managing this major expansion and development push. The sheer magnitude of the $120 million Series B  round received by Pelage Pharmaceuticals  serves as more than just a corporate triumph; it represents a powerful vote of confidence from the global financial community in the transformative potential of regenerative medicine  to address conditions like hair loss that affect vast populations. As Pelage moves its promising Hair Loss Treatment  candidate closer to Phase 3 trials, the entire biotech investment  sector is observing keenly to determine if this substantial capital injection will indeed translate into the medical breakthrough that fundamentally alters the landscape of hair restoration. A helpful way to conceptualize this scale of funding is to view it as fuel:  If early research is using small amounts of specialized gasoline, this $120 million Series B is equivalent to filling the tanks of a large cargo jet. This immense fuel capacity is necessary to perform the long, expensive journey—the Phase 3 trials —required to bring the innovative regenerative medicine  approach to market. 🔖 Sources Not just Rogaine: Biotech investors see promise in a new wave of hair loss treatments Pelage Pharma raises $120 million to advance development of hair loss treatment Pelage Pharmaceuticals Announces $120 Million Series B Financing to Advance Regenerative Medicine Treatments for Hair Loss Pelage Pharma raises $120M series B to untangle roots of hair loss with regenerative med Keywords:  Hair Loss Treatment Hair Loss Treatment

Image credit: goodhousekeeping.com / Push (BBC). Fair use. I f you’re a Call the Midwife  fan, get ready for some exciting news: the BBC is rolling out a brand-new Push BBC maternity drama . This fresh series introduces a spirited ensemble of midwives working in a rural Yorkshire maternity ward — combining heartfelt tension, comedy, and an honest depiction of life on the maternity front lines. Content ⁉️ 1️⃣ What Is Push About? 2️⃣ The Creator: Jessica Knappett’s Vision 3️⃣ Production, Cast & When to Watch 4️⃣ Similar Maternity & Medical Dramas to Watch Now 5️⃣ Why Push Matters (and Why Fans Should Be Excited) 6️⃣What to Keep an Eye On 🔖 Key Takeaways What Is Push About? P ush   unfolds in a small NHS maternity ward in West Yorkshire. The series centers on a tight-knit group of eccentric yet deeply committed midwives operating under challenging conditions. Although the ward is often underfunded and slightly chaotic, its staff are fiercely protective of their domain. Delivering babies is their passion — but the job doesn’t come without its drama. Push  is described as a “laugh-out-loud celebration of the chaotic, high-stakes reality of pulling off a miracle several times a day.” It doesn’t shy away from the grit: blood, sweat, and even “third-degree tears” are part of the daily routine. In their downtime, these midwives are not shy about indulging in corridor flirtations, staff-room gossip, and surprise disco naps in the sluice room. Their camaraderie and idiosyncrasies make them endearing even in the midst of pressure. Jon Petrie, BBC’s Director of Comedy, remarked that the show “feels like Jess and the team have really delivered,” citing its “warmth, friendship and sharp writing.” Geektown Executive Producer Jack Bayles echoed that praise, highlighting the series’ “effortless charm … bags of heart, and a cast of characters as richly diverse as the NHS itself.”   Image credit: goodhousekeeping.com / Push (BBC). Fair use. The Creator: Jessica Knappett’s Vision J essica Knappett, familiar to many from Drifters  and Taskmaster , is spearheading Push  as writer, executive producer, and showrunner. Wikipedia+2Geektown+2 She has said that writing this series was deeply personal: “It is an absolute joy and an immense privilege … ever since I gave birth to my own children, I knew I wanted to birth a show about midwives.” “The NHS is a marvel to me … thankfully this process … I didn’t need stitches.” Geektown+3Geektown+3Sue Terry Voices+3 Her passion for the subject, combined with her comedic instincts, promises a series that will balance humor, emotion, and respect for the realities of maternity care. Production, Cast & When to Watch P ush   is a six-part series produced by Various Artists Ltd, with executive producers including Knappett, Jack Bayles, and Phil Clarke. Geektown+2Sue Terry Voices+2 The BBC Comedy Sitcom Project supported its development.   As of now, no full cast list  has been released. Yahoo Style+1 However, the localization and tone suggest a mix of strong ensemble actors capable of blending comedy and emotional moments. An official UK premiere date has not been confirmed yet. The show is slated to air on BBC One  and stream on iPlayer . Geektown+2Geektown+2 Geektown reports that the release might land in 2026, though that remains unconfirmed.   Similar Maternity & Push BBC maternity drama to Watch Now I f Push  sounds appealing, here are two shows you can check out while waiting: Call the Midwife  – The beloved long-running drama about midwives in London’s East End. All 14 series are currently available on BBC iPlayer. This Is Going to Hurt  – Based on Adam Kay’s memoir, this show chronicles the pressures on junior doctors in obstetrics and gynaecology. It blends sharp comedy with raw emotional stakes and aired on BBC One & iPlayer. Image credit: goodhousekeeping.com / Push (BBC). Fair use. Why Push Matters (and Why Fans Should Be Excited) Grounded in Realism & Heart  With Knappett’s personal experience as inspiration, Push  promises an authentic lens on the joys and challenges of maternity care. It doesn’t glamorize birth — it shows the mess, the marrow, and the miracle. Comedy with Emotional Depth  Unlike dry medical dramas, Push  aims to infuse humor and warmth into high-stress moments. The show’s “high joke rate workplace comedy” ambition makes it a rare blend. Celebrating NHS Workers  The narrative honors the often underappreciated midwives who deliver life in difficult conditions. As Knappett stated, she sees this show almost as a public service tribute to the NHS. Fresh Take on a Familiar Genre While there are many medical dramas, few focus exclusively on maternity in a modern workplace comedy format. Push  fills a niche that Call the Midwife  fans will likely appreciate. What to Keep an Eye On Cast reveal & casting choices  — who plays the midwives? Premiere date announcement  — when and how the show will roll out. Tone balance  — will it lean more comedic or dramatic? Audience reception & critics’ reviews  once it airs — especially from those in healthcare. 🔖 Key Takeaways 🗝️ Push  is BBC’s new maternity workplace comedy created by Jessica Knappett , inspired by her own experiences as a mother. 🗝️ The series is set in a West Yorkshire NHS maternity ward , featuring a quirky yet devoted team of midwives. 🗝️ It combines high-stakes drama, humor, and emotional realism , offering a fresh take on maternity storytelling. 🗝️ The show celebrates the hard-working and under-appreciated NHS staff , portraying both the chaos and joy of childbirth. 🗝️ Fans of Call the Midwife  and This Is Going to Hurt  will likely find Push  equally heartwarming and entertaining. 🗝️ BBC has yet to confirm the official release date , but it will air on BBC One  and stream on BBC iPlayer . 🌐 External sources BBC Comedy Delivers ‘Push’, a New Midwife Sitcom from Jessica Knappett BBC Comedy orders Jessica Knappett’s midwives sitcom 'Push' Push UK & US TV Premiere Date Keywords: Push BBC maternity drama Push BBC maternity drama

Welcome to our Surgical Assistant preparation and certification program. The program offers a self-paced duration. If you meet all the requirements, you can apply through this pathway and complete the payment. The booking section allows you to schedule a call where we’ll provide essential information for your certification process. To ensure eligibility, please visit our services page. Feel free to ask if you need further assistance! 😊

Welcome to our Medical Assistant preparation and certification program. The program offers a self-paced duration. If you meet all the requirements, you can apply through this pathway and complete the payment. The booking section allows you to schedule a call where we’ll provide essential information for your certification process. To ensure eligibility, please visit our services page. Feel free to ask if you need further assistance! 😊

Join our 1-hour BLS course to learn how to recognize life-threatening emergencies, perform high-quality chest compressions, deliver ventilations, and use an AED effectively. Taught according to the latest American Heart Association guidelines. 🩺🌟 For more details, you can visit the Service Page. If you have any other questions, feel free to ask! 😊 What does this course teach? High-quality CPR for adults, children, and infants The AHA Chain of Survival, specifically the BLS components Important early use of an AED Effective ventilations using a barrier device Importance of teams in multirescuer resuscitation and performance as an effective team member during multirescuer CPR Relief of foreign-body airway obstruction (choking) for adults and infants

Video Info Berlin ER 2025 Krank: Berlin (also known as Berlin ER on Apple TV+) follows Dr. Zanna Parker (Haley Louise Jones), a medic escaping a personal crisis in Munich by relocating to Germany's bustling capital. Seeking a fresh start, she takes charge of the emergency room at Berlin's toughest and most overcrowded hospital, known for its chaotic conditions. The series explores her attempts to implement reforms and rebuild her life amidst the relentless pressures, underpaid staff, and high stakes of urban emergency medicine in a challenging healthcare system. Where to see it Buy Watch more TV shows with a free trial of Prime 👉 here. To watch similar TV shows but for free, check out our article 👉 here. Seasons: 1 Comment comments debug Comments Write a comment Write a comment Share Your Thoughts Be the first to write a comment. The Doctor Blake Mysteries 2013-2018 Doctor Detective 2019 Ameku M.D.: Doctor Detective (anime) 2025 Heart Surgeons 2018 Resident Playbook 2025 Doc 2001-2004 Doctor*Ology 2007 The Surgeon 2005 Hospital Playlist 2020-2021 Berlin ER 2025 Doc Martin 2004-2022 Hyper Knife 2025 Breathless 2024 Pulse 2025 The Pitt 2025 Brilliant Minds 2025 DOC 2025 Watson 2025 Mental 2009 St. Denis Medical 2024 - Casualty 1900s 2009 Hawthorne 2009 - 2011 Dr. Ken 2015 - 2017 Mercy Street 2016 - 2017 Dr. Death 2021 - 2023 Go Return Go

Video Info How to Pick a Stock So, you’re ready to dive into the stock market. You’ve heard stories of people building wealth, and you want to be a part of it. But then you’re hit with the big question: with thousands of companies to choose from, how do you actually pick a stock? It can feel like trying to find a needle in a haystack. The good news is that you don’t need to be a Wall Street guru to make smart investment decisions. Successful investing isn't about gambling or chasing hot tips; it's about doing your homework. By breaking down the process into a clear, manageable framework, you can learn to analyze a company, read the market, and make choices that align with your personal financial goals. Comment comments debug Comments Write a comment Write a comment Share Your Thoughts Be the first to write a comment. How to Pick a Stock 3 tips on how to study effectively NCLEX Study Plan 3-Step | NCLEX Review Series Nurse Mike's Tips & Tricks The BEST Way to Study for USMLE Step 1 How to Study Pharmacology in Medical School How to Study Anatomy (in Medical School) How to Pick a Stock 3 tips on how to study effectively NCLEX Study Plan 3-Step | NCLEX Review Series Nurse Mike's Tips & Tricks The BEST Way to Study for USMLE Step 1 How to Study Pharmacology in Medical School How to Study Anatomy (in Medical School) How to Pick a Stock 3 tips on how to study effectively NCLEX Study Plan 3-Step | NCLEX Review Series Nurse Mike's Tips & Tricks The BEST Way to Study for USMLE Step 1 How to Study Pharmacology in Medical School How to Study Anatomy (in Medical School) How to Pick a Stock 3 tips on how to study effectively NCLEX Study Plan 3-Step | NCLEX Review Series Nurse Mike's Tips & Tricks The BEST Way to Study for USMLE Step 1 How to Study Pharmacology in Medical School How to Study Anatomy (in Medical School) How to Pick a Stock 3 tips on how to study effectively NCLEX Study Plan 3-Step | NCLEX Review Series Nurse Mike's Tips & Tricks The BEST Way to Study for USMLE Step 1 How to Study Pharmacology in Medical School How to Study Anatomy (in Medical School) Go Return Go

ST ending Group 1. All three forms of the verb are the same Base Form - Simple Past - Past Participle Burst burst burst Cost cost cost Forecast forecast forecast Back to list English Irregular Verbs Verbs that don't follow regular conjugation patterns. Group 2 ST ending Group 1. All three forms of the verb are the same Go Go Sherringford We designed Sherringford.org to be more than just an educational resource; it's a platform intended to bring a refreshing twist to your daily professional life. Explore Main Pages Home About us Search Pricing Store Points Knowledge Library Blog News Courses Services Community Infotainment MH Colaboration Advertise with us Suggestions Work with us Publish on our blog Publish mentor availability Find a mentor Donations Comply Private Policy Disclosure Terms and Conditions Do Not Sell My Personal Information